ANI Pharmaceuticals Inc (NASDAQ:ANIP) Major Shareholder Meridian Venture Partners Ii L Sells 9,315 Shares

ANI Pharmaceuticals Inc (NASDAQ:ANIP) major shareholder Meridian Venture Partners Ii L sold 9,315 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $69.34, for a total value of $645,902.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Meridian Venture Partners Ii L also recently made the following trade(s):

  • On Friday, August 9th, Meridian Venture Partners Ii L sold 19,860 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.70, for a total value of $1,423,962.00.
  • On Tuesday, August 13th, Meridian Venture Partners Ii L sold 61,697 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.64, for a total value of $4,419,973.08.

Shares of NASDAQ:ANIP opened at $68.54 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $80.22 and a two-hundred day moving average of $70.59. The stock has a market cap of $850.47 million, a P/E ratio of 14.87 and a beta of 2.17. ANI Pharmaceuticals Inc has a 52-week low of $36.92 and a 52-week high of $86.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.26. The company had revenue of $54.36 million during the quarter, compared to analysts’ expectations of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The firm’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.13 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals Inc will post 5.29 earnings per share for the current year.

Several equities research analysts have commented on the company. Canaccord Genuity restated a “buy” rating and issued a $90.00 price objective (up previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Monday, May 13th. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald reissued a “buy” rating and issued a $89.00 price objective on shares of ANI Pharmaceuticals in a research note on Thursday, May 9th. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $89.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in ANI Pharmaceuticals by 3.0% during the fourth quarter. Geode Capital Management LLC now owns 97,459 shares of the specialty pharmaceutical company’s stock worth $4,387,000 after acquiring an additional 2,827 shares during the period. Principal Financial Group Inc. grew its holdings in ANI Pharmaceuticals by 0.8% during the fourth quarter. Principal Financial Group Inc. now owns 67,326 shares of the specialty pharmaceutical company’s stock worth $3,031,000 after acquiring an additional 529 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in ANI Pharmaceuticals by 324.2% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,872 shares of the specialty pharmaceutical company’s stock worth $129,000 after acquiring an additional 2,195 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in ANI Pharmaceuticals during the fourth quarter worth $115,000. Finally, Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 518,427 shares of the specialty pharmaceutical company’s stock worth $23,339,000 after purchasing an additional 6,546 shares in the last quarter. Institutional investors and hedge funds own 64.22% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

See Also: 52-Week High/Low

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.